Imexpharm

Imexpharm Revenue

The The revenue of Imexpharm (IMP.VN) as of Oct 26, 2026 is 2.44 T VND. In the previous year, The revenue was 2.21 T VND — a change of 10.70% (higher).

Revenue

2.44 TVND

YoY

10.70%

Last updated:

In 2025, Imexpharm's sales reached 2.44 T VND, a 10.70% difference from the 2.21 T VND sales recorded in the previous year.

Revenue has compounded at 8.4% per year over the past 19 years to 2.44 T VND.

The Imexpharm Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2020
1.37 T VND
Jan 1, 2021
1.27 T VND
Jan 1, 2022
1.64 T VND
Jan 1, 2023
1.99 T VND
Jan 1, 2024
2.21 T VND
Jan 1, 2025
2.44 T VND
Jan 1, 2026 (e)
2.91 T VND
Jan 1, 2027 (e)
3.28 T VND
The Imexpharm Revenue history
YEARRevenueYoY
est3.28 TVND+12.91%
est2.91 TVND+19.01%
2.44 TVND+10.70%
2.21 TVND+10.59%
1.99 TVND+21.31%
1.64 TVND+29.77%
1.27 TVND-7.51%
1.37 TVND-2.36%
1.40 TVND+18.37%
1.18 TVND+1.66%
1.17 TVND+15.35%
1.01 TVND+4.77%
964.32 BVND+7.49%
897.14 BVND+6.63%
841.32 BVND+2.84%
818.12 BVND+5.38%
776.37 BVND+1.62%
764.00 BVND+15.74%
660.08 BVND+17.48%
561.84 BVND+24.41%
451.60 BVND-14.05%
525.41 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imexpharm Revenue

Imexpharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.37 T VND
262.55 B VND
209.70 B VND
Jan 1, 2021
1.27 T VND
247.43 B VND
189.09 B VND
Jan 1, 2022
1.64 T VND
296.50 B VND
223.54 B VND
Jan 1, 2023
1.99 T VND
381.04 B VND
299.56 B VND
Jan 1, 2024
2.21 T VND
415.26 B VND
320.86 B VND
Jan 1, 2025
2.44 T VND
462.44 B VND
349.14 B VND
Jan 1, 2026 (e)
2.91 T VND
571.32 B VND
389.24 B VND
Jan 1, 2027 (e)
3.28 T VND
649.43 B VND
451.25 B VND

Imexpharm Margins

Imexpharm stock margins

The Imexpharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imexpharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imexpharm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
39.95 %
19.17 %
15.31 %
Jan 1, 2021
38.53 %
19.54 %
14.93 %
Jan 1, 2022
42.43 %
18.04 %
13.60 %
Jan 1, 2023
40.65 %
19.11 %
15.02 %
Jan 1, 2024
38.80 %
18.83 %
14.55 %
Jan 1, 2025
41.03 %
18.94 %
14.30 %
Jan 1, 2026 (e)
41.03 %
19.67 %
13.40 %
Jan 1, 2027 (e)
41.03 %
19.80 %
13.76 %

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Imexpharm's Sales Figures

The sales figures of Imexpharm originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Imexpharm’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Imexpharm's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Imexpharm’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Imexpharm stock

The revenue of Imexpharm is 2.44 T VND in 2025.

The revenue of Imexpharm changed from 2.21 T VND to 2.44 T VND, representing a 10.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Imexpharm historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Imexpharm

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Imexpharm